易瑞沙治疗一线化疗失败非小细胞肺癌的疗效观察

目的观察易瑞沙治疗一线药物化疗失败非小细胞肺癌（NSCLC）的临床疗效。方法将73例一线化疗失败的NSCLC患者随机分为两组，对照组患者36例给予多西紫杉醇＋伊立替康化疗，观察组患者37例给予易瑞沙治疗，随访观察两组患者6个月、1年的生存率及不良反应发生情况。结果两组患者6个月生存率比较差异无统计学意义（P〉0．05）；观察组患者1年生存率及总缓解率高于对照组，差异有统计学意义（P〈0．05）；观察组患者除了皮疹、腹泻外，其他不良反应发生率低于对照组患者，差异有统计学意义（P〈0．05）。结论易瑞沙分子靶向治疗一线化疗失败的NSCLC，可延长患者生存时间，不良反应轻，改善患者生活质量。

Effect observation of Iressa molecular targeted treatment for non-small cell lung cancer who failure of chemotherapy in the first line

Objective To observe the effect of Iressa treating NSCLC after failure of first-line chemotherapy. Methods 73 NSCLC patients suffered from failure of first-line chemotherapy were randomly divided into two groups, 36 cases in control group were treated with docetaxel plus irinotecan chemotherapy, while 37 cases in observation group were treated with Iressa 6 months, 1 year survival rate and toxicity of both groups were followed-up. Results Difference of 6 month survival rate of two groups was not statistically significant （P 〉 0. 05 ） ; 1-year survival rate and overall response rate of observation group were higher than that in control group （ P 〈 0. 05 ）. In addition to the rash and diarrhea, other incidences of adverse reactions of observation group was lower than that in control group （ P 〈 0.05）. Conclusions Molecular-targeted Iressa treatment for NSCLC after failure of first-line chemotherapy can prolong survival time with light toxicity, and improve patients＇ quality of life.